Clearmind Medicine (US:CMND) Globenewswire·2025-04-21 13:15Core Insights - Clearmind Medicine Inc. is hosting a live webinar titled "Gazing Through the Crystal Ball" on May 21, 2025, focusing on the evolving landscape of psychedelic science and business amid changing FDA policies and political climates [1] - The company is a clinical-stage biotech firm dedicated to developing psychedelic-derived therapeutics to address significant under-treated health issues, particularly Alcohol Use Disorder (AUD) [7] Event Details - The webinar will feature a panel of experts, including Rick Doblin, PhD, a pioneer in psychedelic-assisted therapy; Robin Carhart-Harris, PhD, known for his work in psychedelic neuroscience; and Dr. Adi Zuloff-Shani, CEO of Clearmind, who is leading the development of CMND-100 for AUD [2][3][4] - The discussion will be moderated by Shannon Smadella, a recognized advocate in the psychedelic space [6] Company Overview - Clearmind's primary objective is to research and develop psychedelic-based compounds for commercialization as regulated medicines, foods, or supplements [7] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [8]